Therapeutic drugs multiple sclerosis

Use antineoplastic, immunosuppressive, multiple sclerosis therapeutic, antiangiogenic, disease modifying drug, systemic lupus erythematosus therapeutic... 

Das (2003) made an interesting point recently when he suggested that there were currently 371 new products currently on trial against diseases such as Alzheimer s, AIDS, arthritis, cancer, heart disease, and multiple sclerosis (MS). For MS, Serono (Geneva, Switzerland) announced that their new drug Rebif , a form of interferon la, would cost a patient 17,000 a year. Das therefore suggested that supply of many new protein therapeutics for a year was quite likely to exceed 10,000. In spite of this expense, the patient may have no alternatives and this would remain the situation where the disease had inadequate therapy or no treatment at all. 

Schmidt, J., et al. 2003. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 126 1895. 

AIDS, hepatitis, blood disorders, multiple sclerosis and others. At present, another 300 potential therapeutics are in various human clinical trials, although it is impossible to estimate how many of those will actually reach the marketplace. Combinatorial chemistry promises to revolutionize the rate of new-drug development by accelerating initial lead generation. Already, in its approximately 8-year corporate history, combinatorial chemistry has produced about 350 leads in various stages of preclinical development. 

Cannabis is one of the oldest and most widely used drugs in the world. In different Western countries the possible therapeutic use of cannabinoids as antiemetics in patients with cancer or in patients with multiple sclerosis has become an issue, because of the prohibition of cannabis, and has polarized opinion about the seriousness of its adverse effects (1,2). 

Baker D, Pryce G (2003) The therapeutic potential of cannabis in multiple sclerosis. Expert Opin Investig Drugs 12 561-567... 

---